Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines

Endocrine-Related Cancer

Volumn 14, Issue 3, 2007, Pages 839-845

  Catalano, Maria G ^a   Poli, Roberta ^b   Pugliese, Mariateresa ^b   Fortunati, Nicoletta ^b   Boccuzzi, Giuseppe ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; PACLITAXEL; TUBULIN; VALPROIC ACID;

ACETYLATION; ANAPLASTIC CARCINOMA; ANAPLASTIC THYROID CARCINOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; THYROID CARCINOMA;

ACETYLATION; ACETYLTRANSFERASES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; PACLITAXEL; THYROID NEOPLASMS; TUBULIN; VALPROIC ACID;

EID: 35948965312     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0096     Document Type: Article

References (36)

1. Ain KB, Egorin MJ & DeSimone PA 2000 Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10 587-594.
2. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T & Bates SE 2002 Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Molecular Cancer Therapeutics 1 937-941.
3. Brignardello E, Gallo M, Baldi I, Palestini N, Piovesan A, Grossi E, Ciccone G & Boccuzzi G 2007 Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. European Journal of Endocrinology 156 425-430.
4. Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O & Boccuzzi G 2005 Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 90 1383-1389.
5. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, Aragno M & Boccuzzi G 2006 Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. Journal of Endocrinology 191 465-472.
6. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP & Smallridge RC 2006 Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 25 2304-2317.
7. Derry WB, Wilson L & Jordan MA 1995 Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 34 2203-2211.
8. Dowling M, Voong KR, Kim M, Keutmann MK, Harris E & Kao GD 2005 Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biology & Therapy 4 197-206.
9. - symporter and iodine uptake in poorly differentiated thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 89 1006-1009.
10. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG et al. 2001 Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO Journal 20 6969-6978.
11. Gurvich N, Tsygankova OM, Meinkoth JL & Klein PS 2004 Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Research 64 1079-1086.
12. Jordan MA & Wilson L 2004 Microtubules as a target for anticancer drugs. Nature Review Cancer 4 253-265.
13. Jordan MA, Toso RJ, Thrower D & Wilson L 1993 Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. PNAS 90 9552-9556.
14. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H & Wilson L 1996 Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Research 56 816-825.
15. Kebebew E, Greenspan FS, Clark OH, Woeber KA & McMillan A 2005 Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103 1330-1335.
16. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM & Munster PN 2004 Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. Journal of Cellular Biochemistry 92 223-237.
17. Marchion DC, Bicaku E, Daud AI, Sullivan DM & Munster PN 2005 Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Research 65 3815-3822.
18. Markman M 2003 Managing taxane toxicities. Supportive Care in Cancer 11 144-147.
19. Marks PA, Richon VM, Breslow R & Rifkind RA 2001 Histone deacetylase inhibitors as new cancer drugs. Current Opinion in Oncology 13 477-483.
20. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, Osada H, Komatsu Y, Nishino N, Khochbin S et al. 2002 In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO Journal 21 6820-6831.
21. Mielke S, Sparreboom A & Mross K 2006 Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. European Journal of Cancer 42 24-30.
22. Mollinedo F & Gajate C 2003 Microtubules, microtubuleinterfering agents and apoptosis. Apoptosis 8 413-450.
23. Pasieka JL 2003 Anaplastic thyroid cancer. Current Opinion in Oncology 15 78-83.
24. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA & Klein PS 2001 Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry 276 36734-36741.
25. Piperno G, LeDizet M & Chang XJ 1987 Microtubules containing acetylated alpha-tubulin in mammalian cells in culture. Journal of Cell Biology 104 289-302.
26. Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T & Bates SE 2006 Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clinical Cancer Research 12 1547-1555.
27. Rosato RR & Grant S 2003 Histone deacetylase inhibitors in cancer therapy. Cancer Biology and Therapy 2 30-37.
28. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD et al. 2002 Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clinical Cancer Research 8 718-728.
29. Schiff PB & Horwitz SB 1980 Taxol stabilizes microtubules in mouse fibroblast cells. PNAS 77 1561-1565.
30. Tabe Y, Konopleva M, Contractor R, Munsell M, Schober WD, Jin L, Tsutsumi-Ishii Y, Nagaoka I, Igari J & Andreeff M 2006 Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 107 1546-1554.
31. Vigushin DM & Coombes RC 2002 Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 12 1-13.
32. Vivat-Hannah V, You D, Rizzo C, Daris JP, Lapointe P, Zusi FC, Marinier A, Lorenzi MV & Gottardis MM 2001 Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel). Cancer Research 61 8703-8711.
33. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB & Paietta E 1987 Phase I clinical and pharmacokinetic study of taxol. Cancer Research 47 2486-2493.
34. Yeung SC, Xu G, Pan J, Christgen M & Bamiagis A 2000 Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Research 60 650-656.
35. Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S & Matthias P 2003 HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO Journal 22 1168-1179.
36. Zhou J, Liu M, Aneja R, Chandra R & Joshi HC 2004 Enhancement of paclitaxel-induced microtubule stabilization, mitotic arrest, and apoptosis by the microtubule-targeting agent EM012. Biochemical Pharmacology 68 2435-2441.